AURX— Nuo Therapeutics, Inc.

$49M mkt cap

Metric	FY2025	FY2024	FY2023	FY2022
Revenue	$3.3M+142.7%	$1.4M+124.3%	$609K+442.1%	$112K
Revenue	$3.3M+142.7%	$1.4M+124.3%	$609K+442.1%	$112K
Costs of sales	$1.1M+261.8%	$303K+140.2%	$126K+556.3%	$19K
Gross profit	$2.2M+108.8%	$1.1M+120.2%	$482K+418.5%	$93K
Selling, general and administrative	$4.7M+34.5%	$3.5M-3.6%	$3.7M+6.9%	$3.4M
Total operating expenses	$4.7M+34.5%	$3.5M-3.6%	$3.7M+6.9%	$3.4M
Loss from operations	-$2.5M-2.4%	-$2.5M+22.4%	-$3.2M+4.6%	-$3.3M
us-gaap_GrossProfit	$2.2M+108.8%	$1.1M+120.2%	$482K+418.5%	$93K
Interest income (expense), net	-$804-865.7%	$105+103.3%	-$3K-50.4%	-$2K
Gain on settlement of legacy accounts payable obligations	$0-100.0%	$134K	$0-100.0%	$146K
Other income	$5K+1202.7%	$402	$0-100.0%	$5K
Loss before benefit for income taxes	-$2.5M-8.1%	-$2.3M+26.7%	-$3.2M+0.0%	-$3.2M
Net loss	-$2.5M-8.1%	-$2.3M+26.7%	-$3.2M+0.0%	-$3.2M
Basic and diluted (in dollars per share)	-$0.05+0.0%	-$0.05+37.5%	-$0.08+0.0%	-$0.08
Basic and diluted (in shares)	47.3M+4.2%	45.4M+8.0%	42.1M+5.2%	40.0M
Product [Member]
License [Member]

Source: SEC EDGAR XBRL. % change vs prior period shown where available.

Pro feature

Unlock 16 more years of annual history and full quarterly detail on Pro.

Source: SEC EDGAR 10-K and 10-Q filings. Last 4 years annual and quarterly free, full history (up to 20 years) on Pro.